NPM1 and acute myeloid leukemia: Moreover, the results of the randomized AMLSG 15–10 trial exhibited an inferior outcome and decreased OS for the ATRA arm in combination with low-dose cytarabine plus etoposide in older patients (>60 years) with ND NPM1-mutated AML, making it unfit for intensive chemotherapy [123].